SVA SINOVAC BIOTECH LTD Annual reports only
Pharmaceutical Preparations · Nasdaq · SEC CIK 1084201 · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year
Growth
TTM revenue YoY6.8%
TTM net income YoY-165.7%
TTM EPS YoY-165.4%
Revenue 3-yr CAGR-36.0%
Net income 3-yr CAGR—
Margins
Gross margin67.9%
Operating margin-127.0%
Net margin-15.5%
FCF margin-145.4%
EBITDA margin-101.7%
Returns
ROE-0.9%
ROA-0.6%
ROIC (approx.)-6.1%
Asset turnover0.04x
Leverage & solvency
Liabilities / assets25.1%
Debt / equity0.11x
Current ratio4.59x
Interest coverage-49.92x
Cash quality & payout
Operating cash flow / net income8.58x
Accruals ratio4.3%
Payout ratio—
Capex / revenue12.7%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY2025*2025-12-31 | FY2024*2024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $386.01M | $361.37M | $470.17M | $1.47B | $19.37B |
| Cost of revenue | $124.03M | $140.69M | $146.85M | $658.19M | $988.92M |
| Gross profit | $261.98M | $220.69M | $323.32M | $815.24M | $18.38B |
| R&D expense | $216.18M | $270.66M | $350.19M | $478.69M | $152.70M |
| SG&A expense | $332.98M | $420.92M | $598.25M | $836.14M | $602.15M |
| Operating income | -$490.13M | -$505.54M | -$713.98M | -$508.99M | $17.62B |
| Interest expense | $9.82M | $5.64M | $4.94M | $1.26M | $2.84M |
| Pretax income | -$262.10M | $42.84M | -$84.49M | -$48.48M | $17.57B |
| Income tax | -$63.27M | $2.18M | $36.37M | $11.48M | $3.45B |
| Net income | -$59.68M | $90.91M | -$13.49M | $14.47M | $8.12B |
| EBITDA | -$392.68M | -$395.31M | -$556.54M | -$356.28M | $17.70B |
| EPS (basic) | -0.83 | 1.27 | -0.19 | 0.20 | 113.54 |
| EPS (diluted) | -0.83 | 1.27 | -0.19 | 0.20 | 113.44 |
| Dividends declared per share | 55.00 | — | — | — | — |
| Weighted avg. shares (diluted) | 71.86M | 71.86M | 71.85M | 71.76M | 71.60M |
| Balance sheet | |||||
| Cash & equivalents | $488.25M | $335.27M | $1.13B | $3.89B | $11.61B |
| Short-term investments | $5.48B | $9.61B | $9.89B | $6.65B | $1.81B |
| Receivables | $286.34M | $300.89M | $424.94M | $486.59M | $942.74M |
| Inventory | $94.31M | $96.92M | $135.61M | $175.29M | $391.07M |
| Current assets | $7.06B | $10.64B | $11.60B | $11.30B | $14.94B |
| PP&E, net | $706.06M | $880.97M | $951.98M | $989.73M | $855.03M |
| Goodwill | $12.60M | $27.51M | $0 | $0 | $0 |
| Intangibles | $77.68M | $122.58M | $8.52M | $9.70M | $1.48M |
| Total assets | $8.54B | $12.34B | $13.61B | $14.03B | $16.76B |
| Current liabilities | $1.54B | $1.45B | $1.29B | $1.26B | $2.52B |
| Long-term debt | $494.86M | $375.76M | $253.91M | $11.81M | $15.77M |
| Total debt | $494.86M | $375.76M | $253.91M | $11.81M | $15.77M |
| Total liabilities | $2.15B | $2.04B | $1.97B | $1.79B | $3.21B |
| Shareholders' equity | $4.44B | $8.26B | $8.32B | $8.49B | $9.00B |
| Net debt | $6.61M | $40.49M | -$875.22M | -$3.88B | -$11.59B |
| Shares outstanding | 71.86M | 71.86M | 71.86M | 71.72M | 71.72M |
| Cash flow statement | |||||
| Operating cash flow | -$512.18M | -$56.89M | $138.65M | -$798.12M | $15.32B |
| Capital expenditure | $48.92M | $95.96M | $156.16M | $313.86M | $594.21M |
| Free cash flow | -$561.10M | -$152.85M | -$17.52M | -$1.11B | $14.73B |
| Investing cash flow | $4.39B | $456.36M | -$2.70B | -$6.09B | -$2.98B |
| Financing cash flow | -$3.43B | -$823.95M | -$88.55M | -$299.53M | -$1.91B |
| Depreciation & amortization | $97.45M | $110.23M | $157.45M | $152.70M | $85.07M |
| Stock-based compensation | $0 | $0 | $0 | $0 | $7.74M |
| Dividends paid | $3.53B | $947.00M | $328.08M | $247.40M | $1.88B |
Free plan shows the latest 5 periods; Pro shows all 18 🔒
· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.